Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1 1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Reddy V, Yang EJ, Myers B, Liao W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	risankizumab plaque psoriasis il-23 inhibitor biologics safety efficacy Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/9c6744d582d543c9b1218ff58759eaf8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9c6744d582d543c9b1218ff58759eaf8
record_format	dspace
spelling	oai:doaj.org-article:9c6744d582d543c9b1218ff58759eaf82021-12-02T04:34:01ZClinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis1178-7031https://doaj.org/article/9c6744d582d543c9b1218ff58759eaf82020-01-01T00:00:00Zhttps://www.dovepress.com/clinical-evaluation-of-risankizumab-rzaa-in-the-treatment-of-plaque-ps-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1 1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA 94118, USATel +1 661-340-3418Email Vidhatha.reddy@ucsf.eduAbstract: Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.Keywords: risankizumab, plaque psoriasis, IL-23 inhibitor, biologics, safety, efficacyReddy VYang EJMyers BLiao WDove Medical Pressarticlerisankizumabplaque psoriasisil-23 inhibitorbiologicssafetyefficacyPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 53-60 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	risankizumab plaque psoriasis il-23 inhibitor biologics safety efficacy Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	risankizumab plaque psoriasis il-23 inhibitor biologics safety efficacy Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Reddy V Yang EJ Myers B Liao W Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
description	Vidhatha Reddy, 1 Eric J Yang, 2 Bridget Myers, 1 Wilson Liao 1 1San Francisco Department of Dermatology, University of California, San Francisco, CA, USA; 2Virginia Mason Medical Center, Seattle, WA, USACorrespondence: Vidhatha ReddyUCSF Psoriasis and Skin Treatment Center, 515 Spruce Street, San Francisco, CA 94118, USATel +1 661-340-3418Email Vidhatha.reddy@ucsf.eduAbstract: Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.Keywords: risankizumab, plaque psoriasis, IL-23 inhibitor, biologics, safety, efficacy
format	article
author	Reddy V Yang EJ Myers B Liao W
author_facet	Reddy V Yang EJ Myers B Liao W
author_sort	Reddy V
title	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_short	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_full	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_fullStr	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_full_unstemmed	Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis
title_sort	clinical evaluation of risankizumab-rzaa in the treatment of plaque psoriasis
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/9c6744d582d543c9b1218ff58759eaf8
work_keys_str_mv	AT reddyv clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis AT yangej clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis AT myersb clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis AT liaow clinicalevaluationofrisankizumabrzaainthetreatmentofplaquepsoriasis
_version_	1718401139862405120

Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis

Ejemplares similares